T cells targeted against a single minor histocompatibility antigen can cure solid tumors

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• T cells targeting minor histocompatibility (H) antigens are effective against leukemia.
• The efficacy of minor H antigen-specific T cells against solid tumors is largely unknown.

Purpose of the Study:

• To investigate if CD8(+) T cells primed against the H7(a) minor H antigen can eradicate established melanomas in a preclinical mouse model.
• To elucidate the mechanisms by which minor H antigen-specific T cells mediate tumor rejection in solid tumors.

Main Methods:

• Priming CD8(+) T cells against the H7(a) minor H antigen.
• Administering primed T cells to mice with established melanomas.
• Analyzing T cell infiltration, cytokine production (IFN-gamma), tumor angiogenesis, and MHC class I expression.

Main Results:

• Injection of H7(a)-specific T cells cured established melanomas in mice.
• Tumor rejection was mediated by preferential extravasation of interferon (IFN)-gamma-producing T cells.
• Intratumoral IFN-gamma inhibited tumor angiogenesis and upregulated tumor cell MHC class I expression.
• Disseminated T cells did not cause graft-versus-host disease (GVHD) or vitiligo due to low MHC class I on non-hematopoietic host cells.

Conclusions:

• Minor H antigen-specific T cell therapy is a viable strategy for treating solid tumors like melanoma.
• IFN-gamma plays a dual role in tumor rejection: anti-angiogenesis and enhanced tumor recognition.
• The preclinical model provides insights into safe and effective minor H antigen-based immunotherapy for human solid tumors.